



- PRESIDENT**
Claudia Sommer, MD
Germany
- PRESIDENT-ELECT**
Catherine Bushnell, PhD
United States of America
- PAST PRESIDENT**
Lars Arendt-Nielsen
Dr. Med., PhD
Denmark
- TREASURER**
Michael Rowbotham, MD
United States of America
- SECRETARY**
Mary Cardosa, MBBS
Malaysia
- COUNCILORS**
- Nadine Attal, MD, PhD
France
- Sushma Bhatnagar, MD, MSc
India
- Fiona Blyth, PhD
Australia
- Margarita Calvo, PhD
Chile
- Robert Coghill, PhD
United States of America
- Allen Firley, MD, FRCP, FAAP
Canada
- Jordi Miro, PhD
Spain
- Supranee Niruthisard, MD
Thailand
- Romy Parker, PhD
South Africa
- Serge Perrot, MD, PhD
France
- Esther Pogatzki-Zahn
Prof. Dr. Med.
Germany
- Andrew Rice, MB BS, MD
FRCP, FRCA, FFPMRCA
United Kingdom
- Michele Sterling, PhD
MPhy, BPhy, FACP
Australia
- Jennifer Stinson, RN-EC
MScN, PhD, CPNP, FAAN
Canada
- Takahiro Ushida, MD, PhD
Japan

9 August 2022

Rinkle Malani, PhD
MGM School of Physiotherapy
N-6 Cidco
Aurangabad, 431003
India

Dear Dr. Rinkle Malani,

I am very happy to inform you that you have been awarded the 2022 IASP Developing Countries Grant for your project "A Multidisciplinary Educational Training Course for Physical Therapists on managing common musculoskeletal pain conditions in Maharashtra, India."

In selecting you for the award, the Developing Countries Working Group acknowledged how important this work is to pain research. IASP looks forward to hearing about the outcomes of the project and its impact on the pain community.

On behalf of IASP, please accept my congratulations to you as the recipient of this prestigious award.

Best regards,

Colleen Delaney Eubanks, CAE
Chief Executive Officer
International Association for the Study of Pain

IASP Secretariat • 1510 H Street N.W., Suite 600 • Washington D.C., USA 20005-1020
T +1202.856.7400 • F +1202.856.7401 • iasp-pain.org

PDF is a text document, not a graphic image.



Director
MGM School of Physiotherapy
Aurangabad

Best
22.8.23

IASP Developing Countries Project:
Initiative for Improving Pain Education



IASP
INTERNATIONAL ASSOCIATION
FOR THE STUDY OF PAIN

Grant Agreement

Primary Organizer:	Dr Rinkle Malani	
Administering Institute:	Mhatma Gandhi Mission School of Physiotherapy, Aurangabad	
Amount:	USD\$ 8,466	one-time amount
Duration:	6 September 2022 to 6 September 2023	
Project Title:	A Multidisciplinary Educational Training Course for Physical Therapists on Managing Common Musculoskeletal Pain Conditions in Maharashtra, India	

Your signature below indicates acceptance of the following grant conditions:

05

Financial/Legal: Rinkle Malani
IASP is awarding a one-time IASP Developing Countries Project: Initiative for Improving Pain Education Grant of USD\$ 8,466 over one year during the period of September 6, 2022 - September 6, 2023 for the

A Multidisciplinary Educational Training Course for Physical Therapists on managing common musculoskeletal pain conditions in Maharashtra, India

This Grant Agreement covers the period from September 6, 2022 - September 6, 2023 pending compliance with terms and conditions as outlined. Expenses incurred before and after this period are not covered by this grant.

- IASP will send the grant funds to the institution and not the individual. The institution or organization administering the account is a not-for profit institution or organization.
The institute will not take any indirect/overhead charges or administrative fees from the grant award.
- After the grant completion, the institute will provide a full financial statement showing the expenditure of the funds, and will maintain adequate records (list of expenses and copies of receipts) to enable easy confirmation of the expenditure of the funds.
- The recipient agrees to inform IASP if any changes occur during the educational project regarding the budget, the educational project as originally described in the application, or change of the institute.
- Any funds remaining after the project should be returned to IASP no later than 60 days upon completion of the project, unless an extension of the project period is granted by IASP due to unusual circumstances.
- IASP reserves the right to discontinue, modify or withhold any payments to be made under this grant award or to require a partial refund of any grant funds, if it, in IASP's sole discretion, such action is necessary: (1) because Recipient has not fully complied with the terms and conditions of this Grant; (2) to protect the purpose and objectives of the grant or any other donor activities of IASP; or (3) to comply with any law or regulation applicable to the Recipient, to IASP, or this Grant.
- The Recipient agrees to maintain IASP membership status for the duration of the Project, as outlined in this Grant Agreement.



A/c. ID	0076104000791526 INR 076 MGM SCHOOL OF PHYSIOTHERAPY		
A/c. Status	ACTIVE	A/c. Status Date	07-12-2020
A/c. Open Date	07-12-2020	A/c. Close Date	
GL Subhead	10400	A/c. Type	CUSTOMER ACCOUNT
Opening Bal.	INR 26,24,786.00 CR.	Available Amt.	INR 26,99,959.47 CR.
Closing Bal.	INR 26,99,959.47 CR.	Effective Available Amt.	INR 26,99,959.47 CR.
Funds in Clg.	INR 0.00 CR.	Float Bal.	INR 0.00 CR.

Tran. Date	Value Date	Instr. No.	Particulars	CCY	Debit Amt.	Credit Amt.	Bal.
01-02-2023	01-02-2023		IMPS/303207411244/ASHOK VISH/ICICI B/XX8035/Aishwa	INR		3,000.00	26,27,786.00CR.
01-02-2023	01-02-2023		UPI/303285714931/SHWETA RAMDAS GHODKE	INR		3,000.00	26,30,786.00CR.
01-02-2023	01-02-2023		UPI/303259474321/APURVA SANJIV PATIL	INR		1,00,000.00	27,30,786.00CR.
01-02-2023	01-02-2023		NEFT-MAHBH23032362115-HARI OM	INR		2,00,000.00	29,30,786.00CR.
02-02-2023	02-02-2023		NEFT-NKGSH23033582902-BISWAJIT	INR		1,00,000.00	30,30,786.00CR.
03-02-2023	03-02-2023		UPI/303440934584/JAY RAJESH KADAM	INR		20,000.00	30,50,786.00CR.
03-02-2023	03-02-2023		UPI/303411796429/MAYURESH RAJENDRA PADALKAR	INR		20,000.00	30,70,786.00CR.
04-02-2023	04-02-2023		UPI/303555137567/GAURAV CHANDRAKANT MHASKE	INR		1,200.00	30,71,986.00CR.
04-02-2023	04-02-2023		UPI/303555265450/GAURAV CHANDRAKANT MHASKE	INR		1,200.00	30,73,186.00CR.
04-02-2023	04-02-2023		UPI/303522272242/RAJMAYUREE RAJARAM SHELKE	INR		10,000.00	30,83,186.00CR.
04-02-2023	04-02-2023		UPI/303548844822/GAURAV CHANDRAKANT MHASKE	INR		1,200.00	30,84,386.00CR.
04-02-2023	04-02-2023		NEFT-YESB30359365481-SANGITA K	INR		2,00,000.00	32,84,386.00CR.
04-02-2023	04-02-2023		IMPS/303514805342/LALITA NAN/State B/XX4175/MOBLTA	INR		1.00	32,84,387.00CR.
04-02-2023	04-02-2023		IMPS/303514808215/LALITA NAN/State B/XX4175/MOBLTA	INR		1.00	32,84,388.00CR.
06-02-2023	06-02-2023		UPI/303728231928/JUNNESHWAR LAXMAN BIDVE	INR		500.00	32,84,888.00CR.
06-02-2023	06-02-2023		UPI/303726584319/TAJUDDIN BURHANUDDIN CHITTAPURE	INR		500.00	32,85,388.00CR.
07-02-2023	07-02-2023		CITIR52023020700700410 INTERNATIONAL ASSOCIATION F	INR		6,74,206.47	39,59,594.47CR.
10-02-2023	10-02-2023	359845	MGM SCHOOL OF PHYSIOTHERAPY	INR	41,250.00		39,18,344.47CR.
13-02-2023	13-02-2023		MGM INSTITUTE OF HEALTH SCIENCES	INR		1,66,615.00	40,84,959.47CR.
15-02-2023	15-02-2023	485966	MGM INSTITUTE OF HEALTH SCIENCES	INR	13,85,000.00		26,99,959.47CR.

Approved
(Signature)

MGM Medical College

N-6 , CIDCO, Aurangabad

Clinical Research Services Receipts

Ledger Account

1-Apr-2022 to 31-Mar-2023

Page 1

Date	Particulars	Vch Type	Vch No.	Debit	Credit
1-4-2022	By Opening Balance				11,61,220.00
13-4-2022	By IDBI BANK A/c 0376104000000107	Receipt	32		3,459.00
		<i>Being Received through NEFT ICIB221030096731- Vedic Li</i>			
21-4-2022	By IDBI BANK A/c 0376104000000107	Receipt	49		29,174.00
		<i>Being Received through NEFT IN10N220421001GGK-CLIANTHA</i>			
28-4-2022	By IDBI BANK A/c 0376104000000107	Receipt	69		9,01,848.00
		<i>Being Received through NEFT IN118221934919644-ABIogene</i>			
17-5-2022	By IDBI BANK A/c 0376104000000107	Receipt	124		22,500.00
		<i>Being Received through NEFT N137221213872508 JSS MEDI</i>			
27-5-2022	By IDBI BANK A/c 0376104000000107	Receipt	159		1,50,001.20
		<i>Being Received through NEFT HSBCN22147469589/ GEORGE C</i>			
2-6-2022	By IDBI BANK A/c 0376104000000107	Receipt	177		97,308.00
		<i>Being Received through NEFT -AXMB221538927671 Doclin C</i>			
13-6-2022	By IDBI BANK A/c 0376104000000107	Receipt	211		4,81,258.51
		<i>Being Received through NEFT -CMS2641038445-DIAGNOSEARC</i>			
20-6-2022	By IDBI BANK A/c 0376104000000107	Receipt	229		4,13,739.00
		<i>Being Received through NEFT -UBINR22022062001298241 Cliniinifinity Clinical reserch</i>			
29-6-2022	By IDBI BANK A/c 0376104000000107	Receipt	260		85,000.00
		<i>Being Received through NEFT -N180220144671980-SCITUSPH</i>			
6-7-2022	By IDBI BANK A/c 0376104000000107	Receipt	288		20.00
		<i>Being Received through NEFT -HSBCN22187716006-SYNGENE</i>			
18-7-2022	By IDBI BANK A/c 0376104000000107	Receipt	324		1,02,141.00
		<i>Being Received through IMPS/219918069395 /Grapecity/Buld15</i>			
	By IDBI BANK A/c 0376104000000107	Receipt	325		54,990.00
		<i>Being Received through IMPS/219918069642 /Grapecity/Buld15</i>			
30-8-2022	By IDBI BANK A/c 0376104000000107	Receipt	438		1,76,715.00
		<i>Being Received through NEFT -IN10N22083000L77-CLIANTHA</i>			
	Carried Over				36,79,373.71

continued ...

MGM Medical College

Clinical Research Services Receipts Ledger Account : 1-Apr-2022 to 31-Mar-2023


Date	Particulars	Vch Type	Vch No.	Debit	Credit
	Brought Forward				36,79,373.71
1-9-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT -CMS2799215421-Wockhardt L</i>	Receipt	439		1,35,000.00
7-9-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT- HSBCN22250490774-SYNGENE</i>	Receipt	454		75,000.60
13-9-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT- HSBCN22256300149-Parexel</i>	Receipt	466		75,000.00
5-10-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT -HSBCN22278797078-NOVOTECH</i>	Receipt	520		75,000.00
7-10-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT -HSBCN22280224621-SYNGENE</i>	Receipt	529		30,000.60
21-10-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT CMS2904995849-Diagosearc</i>	Receipt	569		76,668.00
31-10-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT 000279987971 -SIRO CLINPHA</i>	Receipt	587		85,000.00
3-11-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT YESB23079535211-JSS Medic</i>	Receipt	597		76,500.00
17-11-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT CITIN22367298655-ICON CLI</i>	Receipt	630		30,000.00
22-12-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT 30532964671DC-Grapecity R</i>	Receipt	729		85,556.00
23-12-2022	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT IN10N2212301AUO-Cliantha</i>	Receipt	733		79,560.00
5-1-2023	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT 30687302901DC-Grapecity R</i>	Receipt	763		1,28,143.00
	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT HSBCN23005895871-NOVOTECH</i>	Receipt	764		30,000.00
21-2-2023	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT CMS3134151482-Wockhard L</i>	Receipt	883		33,750.00
3-3-2023	By IDBI BANK A/c 0376104000000107 <i>Being Received through NEFT HSBCN23062915313-NOVOTECH</i>	Receipt	908		30,000.00
	Carried Over				47,24,551.91

MGM Medical College

Clinical Research Services Receipts Ledger Account : 1-Apr-2022 to 31-Mar-2023

Page 3

Date	Particulars	Vch Type	Vch No.	Debit	Credit
	Brought Forward				47,24,551.91
9-3-2023	By IDBI BANK A/c 0376104000000107	Receipt	925		1,23,433.00
	<i>Being Received through IMPS/306811081998 /OXYGENCLIN</i>				
18-3-2023	By IDBI BANK A/c 0376104000000107	Receipt	960		9,450.00
	<i>Being Received through NEFT -IN10N230318005T9-Cliantha</i>				
24-3-2023	By IDBI BANK A/c 0376104000000107	Receipt	970		2,27,662.00
	<i>Being Chq No 456381 Received from Aurangabad health Care And Research LLP</i>				
28-3-2023	By IDBI BANK A/c 0376104000000107	Receipt	988		31,068.00
	<i>Being Received through NEFT-000853335380 Ardent Clini</i>				
	To	Closing Balance		51,16,164.91	51,16,164.91
				51,16,164.91	51,16,164.91


Accountant
MGM'S Medical College
Aurangabad.



MGM INSTITUTE OF HEALTH SCIENCES
(Deemed University u/s 3 of UGC Act, 1956)
Grade 'A++' Accredited by NAAC
Non Government Project

Sr. No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/ Co Investigator	Name of the funding agency	Type (Government/ Non-Government)	Department of Pricipal Investigator/ Co- Inveatigator	Year of Award	Funds provided (INR in Lakhs)	Duration of Project
2014-15								
1	Validation of ingenious device designed by ACTOFIT for kinematic analysis of joint motion	Dr. Rajani Mullerpatan	ACTOFIT	Non - Government	Physiotherapy Navi Mumbai	2014	0.3	1 yrs
2	Establishment of MGM Centre of Human Movement Science at MGM School of Physiotherapy	Dr. Rajani Mullerpatan	International Society of Biomechanics	Non - Government	Physiotherapy Navi Mumbai	2014	74.6683	3 yrs
2015-16								
1	Non Invasive TB Triage & Patient Mapping platform using breath via Low cost titanium dioxide Nanotube sensor	Dr. Samir Pachpute (PI)	IKP Knowledge Park	Non - Government	Microbiology Navi Mumbai	2015	49.9	1 yrs
2	The effects of labour and birth positioning on pelvic dimensions: gaining further insight to improve the birth experience	Dr. Rajani Mullerpatan	Shastri foundation	Non - Government	Physiotherapy Navi Mumbai	2015	1.12	1 yrs
3	Clinical Evaluation of Breath-Based point of care test for diagnosis of Pulmonary Tuberculosis	Dr. Pradeep Potdar	University of UTAH, USA & Nanosynth	Non - Government	Respiratory Medicine	2016	66	1 yrs
4	A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect and Safety of Test Biscuits as Compared to Placebo Biscuits in Regulating Blood Glucose Level in Subjects With Type 2 Diabetes Mellitus.	Dr. Deepak Bhosle	Karmik life sciences	Non - Government	Pharmacology Aurangabad	2016	3.27866	Ongoing

5	A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel Group, Multi-Centric, Clinical Study To Evaluate The Therapeutic Bio-Equivalence Of Two Tacrolimus 0.1% Topical Ointment Formulations In Adult Patients With Moderate To Severe Atopic Dermatitis.	Dr. Ashish Deshmukh	Lambda Therapeutic Research Limited	Non - Government	TB & Chest Aurangabad	2016	0.9576	Ongoing
6	A randomized, multi center, open label, two-treatment, two-period, two-sequence, multiple dose, crossover, steady state bioequivalence study of Everolimus tablets, 10 mg of Biocon Limited, India vs. Afinitor® (Everolimus) tablets, 10 mg of Novartis Pharmaceuticals Corporation, USA in advanced renal cell carcinoma (RCC) patients	Dr. Chandrashekhar Tamane	Veeda Clinical Research Pvt. Ltd,	Non - Government	Oncology Aurangabad	2016	1.12928	Ongoing
2016-17								
1	A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study Of Paclitaxel Injection Concentrate For Nano-Dispersion (PICN) And Abraxane® In Subjects With Locally Recurrent Or Metastatic Breast Cancer.	Dr. Chandrashekhar Tamane	Sun Pharma Advanced Research Company Ltd (SPARC)	Non - Government	Oncology Aurangabad	2016	1.12928	Ongoing
2	Real world, Non-interventional, Observational Study of Hydroxyzine hydrochloride in chronic pruritus	Dr. H R Jerajani	Clinresearch Healthcare solution pvt ltd	Non - Government	Dermatology Navi Mumbai	2016	2.1	Ongoing
3	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery. Protocol Number : CV185-158	Dr. Girish Gadekar	PPD Pharmaceutical Development India Pvt Ltd	Non - Government	Orthopaedics Aurangabad	2016	19.2	Ongoing
4	Real world, non-interventional, observational study of Venusia Max Cream as Moisturizer in Psoriasis	Dr. H R Jerajani	Bio Quest pvt ltd	Non - Government	Dermatology Navi Mumbai	2017	2.1	Ongoing
5	To evaluate efficacy and safety of Bacillus clausii (2 billion spores/5 ml) suspension as an add on therapy to standard of care in acute viral diarrhoea in children	Dr. Nimain Mohanty	Wockhardt Ltd	Non - Government	Paediatrics Navi Mumbai	2017	11.49	Ongoing

6	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical Povidone-Iodine (PVP-I, 2% [W/W]) in Pediatric Subjects for the Treatment of MolluscumContagiosum.	Dr. Ashish Deshmukh	JSS Clinical Research Limited	Non - Government	TB & Chest Aurangabad	2017	3.495	Ongoing
7	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of LNP1892 (Monotherapy) in Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT), On Dialysis and Not on Dialysis. Protocol Number: LRP/LNP1892/2016/007; Version No.: 1.2, Dated 15 Dec 2016	Dr. Sudhir Kulkarni	LUPIN	Non - Government	Nephrology Aurangabad	2017	1	Ongoing
8	A randomized, open label, parallel-group, active-comparator controlled, multi-center study to evaluate the efficacy and safety of Llipristal acetate (5 mg tablets), as compared with Leuprolide acetate (3.75 mg intramuscular injection) for 12 weeks, in the preoperative treatment of moderate to severe symptomatic uterine fibroids	Dr. Lakshmi Rachkonda	Clantha Research Limited	Non - Government	OBGY Aurangabad	2017	0.7902	Ongoing
9	Title An open label, Two Arms, Comparative, Phase IV Clinical Study evaluating safety and efficacy of Oratil LZ (combination of Cefuroxime 250mg + Linezolid 600mg) versus Linezolid 600mg in patients with Diabetic Foot Infections.	Dr. Anuradha Patil	Macleods Pharmaceutical Ltd	Non - Government	Pathology	2017	1.4375	Ongoing
10	An Open Label Prospective, comparative, randomized, clinical study evaluating efficacy and safety of treatment A (Tamsulocin 0.4 mg Modified release capsule) versus treatment B (FDC Deflazacort 30 mg plus Tamsulocin 0.4 mg Tablet) in the patients with ureteral stone.	Dr. Prashant Darakh	Macleods Pharmaceutical Ltd	Non - Government	Urology Aurangabad	2017	2.4	Ongoing

11	A Two arm, Comparative, Parallel, Randomized, double-blind, double-dummy Clinical study to evaluate and compare the efficacy and safety of Cefrine (combination of cefdinir 300 mg + lactobacillus 60 million cells) Capsule versus Cefuroxime 250 mg Tablet in the treatment of patients with Upper Respiratory Tract Infections.	Dr. Rajendra Bohra	Macleods Pharmaceutical Ltd	Non - Government	ENT Aurangabad	2017	2.4	Ongoing
12	A Prospective, Multicentric, Phase IV Clinical Study evaluating safety and efficacy of Leuprorelin 3.5mg Injection plus Enzomac Tablet (Trypsin 96 mg + Bromelain 180 mg + Rutoside Trihydrate 200 mg) versus Leuproretin 3 smg Injection in the treatment of patients diagnosis with Endometriosis Protocol No.: CT-205-LEEN-2016	Dr. Swati Shiradkar	Macleods Pharmaceutical Ltd	Non - Government	Community Medicine	2017	1.725	Ongoing
13	An open label, Two arm, Comparative, Randomized Phase IV Clinical Study evaluating efficacy and safety of Alrista Forte (Epalrestat 150 Mg + Methylcobalmin 1500 Mcg + Pregabalin 150 Mg) Tablet versus Pregabalin 150 Mg Capsule in patients with Diabetic Neuropathy	Dr. Deepak Bhosle	Macleods Pharmaceutical Ltd	Non - Government	Pharmacology Aurangabad	2017	2.4	Ongoing
2017-18								
1	26 Week, Multicenter, randomized, placebo controlled, double blind, parallel group, phase 3 trial with a 26 week safety extension period evaluating the safety and efficacy of Dapagliflozin 5 and 10 mg and saxagliptin 2.5 and 5 mg in pediatric patients with type 2 diabetes mellitus who are between 10 and below 18 years of age	Dr. Deepak Bhosale	Astrazeneca Pharma India Ltd	Non - Government	Pharmacology Aurangabad	2017	3.77323	Ongoing

2	A 24'week, randomised, double'blind, double-dummv parallel group, multi cenire, active'controlled study to evaluatc efficacy and safety ofremogliflozin etabonate in subjects with type'2 diabetes mcllitus.	Dr. Deepak Bhosale	Glenmark Pharmaceutical Ltd	Non - Government	Pharmacology Aurangabad	2017	25.65	Ongoing
3	A Study to Evaluate the Effect of Dapagliflozin on Incidence of Worsening Hearl Failure or Cardiovascular Death in in Patients lvith phronic Heart Failure with Reduced Ejection F-raction.	Dr. Prashant Udgire	Astrazeneka Pharma India Ltd	Non - Government	Plastic Surgery Aurangabad	2017	63.3	Ongoing
4	Inj- TR2SERVE :A comprehensive program to train , triage, and improve services for unintended childhood injuries in India	Dr. Maninder singh Setia	Grand Challenges Canada	Non - Government	OBGY Navi Mumbai	2018	0.98545	Ongoing
5	Phase 3 Multicenter Double blind study to evaluate the long term safety and efficacy of barciunib in adult patients with atopc dermatitis	Dr. H R Jerajani	Elli Lilly Company (India) Pvt Ltd Gurgaon Haryana	Non - Government	Dermatology Navi Mumbai	2018	24.25868	Ongoing
6	A Multicenter Randomized double blind placebo controlled study to evaluate the efficacy and safety of baricitinib in adult patients with moderate to severe atopc dermatitis	Dr H R Jerajani	Elli Lilly Company (India) Pvt Ltd Gurgaon Haryana	Non - Government	Dermatology Navi Mumbai	2018	15.7825	Ongoing
2018 -19								
1	Biomechanical analysis and energy expenditure of traditional, chair and wall Suryanamaskar	Dr. Rajani Mullerpattan	Sancheti College of Physiotherapy	Non - Government	Physiotherapy Navi Mumbai	2018	0.172	1 yrs
2	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function	Dr. Prashant Udgire	Sanofi- Synthelabo Pvt Ltd	Non - Government	Cardiology Aurangabad	2018	112.925	Ongoing

3	A Randomized, Double-Blind, Placebo-Controlled, three-arm, Parallel Design, Multiple site, Study to Evaluate the Therapeutic equivalence and Safety of Tacrolimus Ointment,0.1% (Encube Ethicals Private Limited) with Protopic® - (Tacrolimus Ointment 0.1% (Astellas Pharma US, Inc) in the treatment of Moderate to Severe Atopic Dermatitis.	Dr. Ashish Deshmukh	Accutest	Non - Government	Skin and VD Aurangabad	2018	10.97	Ongoing
4	A Multicentric, Open lable, Randomized, Comparative, clinical study evaluating safety and Efficacy of Fixed Dose combination of Trypsin 48 mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg enteric coated tablet versus Serratiopeptide 10 mg enteric coated tablet in patient for heling potential in surgical wound after minor surgery.	Dr. Mahendra Surywanshi	Macleods Pharmaceutical Ltd	Non - Government	Surgery Aurangabad	2018	2.88	Ongoing
5	A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add on to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension.	Dr. Deepak Bhosle	IQVIA HDS (India) Private	Non - Government	Pharmacology Aurangabad	2019	20.3976	Ongoing
6	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study.	Dr. Shivaji Pole	SIRO Clinpharm Pvt. Ltd.	Non - Government	Interventional Radiology Aurangabad	2019	10.7085	Ongoing
2019 -2020								
1	Rotasili ® vaccine intussusceptions surveillance in Kerala, Karnataka , Maharashtra and Gurjarat, India	Dr. Mohd Haseeb	Bill and Melinda Gates Foundation	Non- Government	Medicine	2020	383400	2 year
2	Major neurological complications following central neural blockade – A pilot study in Aurangabad city	Dr. Sadhana Kulkarni	MGM Institute of Health Sciences, Navi Mumbai (faculty project)	Non- Government	Emergency Medicine	2019	25,000	1 Year
3	Safety and Efficacy of Lipiodol Ultra fluid in association with Surgical Glues during Vascular Embolization. (IV) Protocol No: LUF-44-001	Dr Shivaji Pole, Dr Ejaj Patel	GUERBET	Non- Government	Radiology	2019	Rs.1,07,085/- (Per Patient)	180 days

4	A Multicentric, Randomized, Open label, Clinical trial To Evaluate Efficacy and Safety of Tapentadol Nasal Spray in comparison to Tramadol Immediate release Capsule and Intravenous injection in patients with Post operative moderate to severe pain. PNo: CT/TAPE/PAIN/17/03	Dr Tejendersingh Chhabda, Dr Amey Chakkarwar	SIRO CRO	Non- Government	Surgery	2019	Rs. 27,600/- (Per Patient)	180 days
5	Multi centre cross sectional epidemiological study to characterize the prevalence and distribution of lipoprotein (a) levels among patient with established cardiovascular diseaseP No : CTQJ23A12001	Dr Prashant Udgire	Novartis	Non- Government	Cardiology	2019	Rs 8,400/- (Per Patient)	180 days
6	A Randomized,Open label, Prospective,Comparative Multicentre, Parallel group Active controlled Phase III Study evaluate safety and efficacy of Ropivacaine readyfusor 2mg/ml versus Ropivacaine ballon pump infusor 2mg/ml as continuous surgical site infusion for treatment of post surgical Pain in lower abdominal Laprotomy. P. No:CP/04/18	Dr Vasanti Kelkar	JSS	Non- Government	Anaesthesiology	2019	Rs 8,400/- (Per Patient)	180 days
7	A Prospective, Single-center, Open-label, Randomized, Parallel group, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of CefpodoximeProxetil 200 mg + Clavulanic acid 125 mg versus Amoxicillin 500 mg + Clavulanic acid 125 mg in the Treatment of Patients with Upper Respiratory Tract Infections.	Dr Rajendra Bohra	Macleods Pharmaceuticals Ltd.	Non- Government	ENT	2019	Rs 6,000/- per patient	180 days

8	A Prospective, ,Double Blind, Randomized Parallelgroup,vehicle controlled,Multicentre Clinical Study to evaluate Safety and Bioequivalence of Mupirocin Cream USP 2% (Supplied by Glasshouse Pharmaceuticals Limited Canada) using Mupirocin cream 2% (Manufactured by :Glenmark Pharmaceuticals Inc:USA) as a reference product,in subjects with secondarily Infected Traumatic Skin Lesions P.No : GH-SL-IN-01	Dr.Ashish Deshmukh	JSS	Non- Government	Dermatology	2019	Rs 15,000 per patient	180 days
9	A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease	Dr Umar Quadri	GSK/PPD	Non- Government	Emergency Medicine	2020	Rs 7,27,291/-	1 Year
10	A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19.	Dr. Umar Quadri	Biosphere Clinical Research Pvt. Ltd	Non- Government	Emergency Medicine	2020	Rs 18,000/-	1 Year
11	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab™ in patients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance Life Sciences	Non- Government	Dermatology & Pharmacology	2020	Rs 36,344/-	1 Year
12	An open label, randomized, active-controlled, multi-centric phase-ii/iii study in indian toddlers and infants to assess the immunogenicity and safety of siiplhexasiilm (dtwp-hepb-ipv-hib) vaccine in comparison with siiplpentavac (dtwp-hepb-hib) + poliovac (ipv) vaccines, administered as separate injections.	Dr. Deepak Tayade	Serum Institute of India	Non- Government	Community Medicine	2020	Rs 26,300/-	1 Year
13	A randomized double blind placebo controlled study to evaluate the efficacy and safety of cordyceps capsules (Food supplement) as an additional on therapy in patient with mild to moderate covid -19 infection	Dr. Sagar Sinha Dr. Siddharth Dubhasi, (AIIMS, Nagpur) Dr. Jayashree Ghanekar, Dr. Sameer Kadam, Dr. Parineeta Samant	M/S Ambosia Food Farm Co. Uttrakhand	Non- Government	Emergency Medicine , Surgery, Biochemistry and AIIMS, Nagpur	2020	14,72,000	1 Year
14	Survey to collect voice samples of patients and age matched healthy individuals P No: VoQuest01	Dr. Deepak Bhosle	Quest	Non- Government	Pharmacology	2020	Rs.100 /- (Per Patient)	180 days

15	A Multicenter, Phase III, Double-Blind, Randomized, Placebocontrolled Study To Evaluate The Efficacy Of Recombinant Bcg Vpm1002 In Reducing Infection Incidence And Disease Severity Of Sars-Cov-2/ Covid-19 Among High-Risk Subjects P No: SII-Rbcg/ COVID-19/IN-01	Dr. Deepak Tayade	Serum Institute of India Pvt. Ltd	Non- Government	Community Medicine	2020	Rs 18,200/- (Per Patient)	180 days
16	A Phase III, Multicentre, Randomized, Double Blind, Parallel group, Comparative Clinical Study to evaluate Efficacy and Safety of Ropivacaine Hydrochloride 0.75% (7.5mg/ml) in Dextrose 8% (80 mg/ml) injection compared to Bupivacaine Hydrochloride 0.5% (5mg/ml) in Dextrose 8% (80mg/ml) injection for subjects undergoing lower limb orthopedic surgeries under spinal anaesthesia P No: BCR/RPD/01	Dr. Vasanti Kelkar	Neon	Non- Government	Anaesthesiology	2020	RS 10,000/- (Per Patient)	180 days
17	A Comparative, Randomized, Two arm, Double blind, Parallel Group, Multicentre, Phase III Clinical study to Evaluate the Efficacy, Safety, and Tolerability of Netarsudil Ophthalmic Solution 0.02% vs Timolol maleate Eye drops 0.5% in treatment of elevated Intraocular Pressure (IOP) in subjects with Open Angle Glaucoma or Ocular Hypertension P No: APL/CT/18/03	Dr. Jyotika Mishrikotkar	Mediclin Clinical Research	Non- Government	Ophthalmology	2020	Rs 18,500 (Per Patient)	180 days
18	A prospective, Multicentre, Randomized, Double blind, Phase 3 study to evaluate the safety and efficacy of a gel formulation of Esmolol hydrochloride (Galnobax) in treating Diabetic Foot Ulcer P No: NG-A16	Deepak Bhosale	JSS	Non- Government	Pharmacology	2020	Rs 80,000 (Per Patient)	180 days
19	A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian Covid-19 Patients P No: GPL/CT/2020/004/III	Dr. Anand Nikalje	Glenmark	Non- Government	Pharmacology	2020	Rs 95,000/- (Per Patient)	180 days
20	A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19.	Dr. Umar Quadri	MGC Pharma	Non- Government	Emergency Medicine	2020	Rs 18,000/- per patient	180 days

21	A Randomized, Open Label, Single Centre, Observational, Prospective, Clinical Study to Evaluate the Efficacy and Safety of GanjhuVir syrup and tablet when administered along with Standard of Care (SOC) and compared against SOC in Covid-19 positive patients.	Dr.Umar Quadri	Radhika Ayurveda Research and Development	Non- Government	Emergency Medicine	2020	Rs 6,666/- per patient	180 days
22	A Randomized, Open Label, Parallel Efficacy, Active Control, Multi- Centre Exploratory Drug Trial to Evaluate Efficacy and Safety of an Ayurvedic Formulation- II (SanshamaniVati Plus) as Adjunct Treatment to Standard of Care for the management of Mild to Moderate COVID-19 Patients.	Dr. Syed Umar Qudari	AYUSH CSIR	Non- Government	Emergency Medicine	2020	Rs 15,000/- per patient	180 days
23	An open label, randomized, active-controlled, multi-centric phase-ii/iii study in indian toddlers and infants to assess the immunogenicity and safety of siiplhexasiilm (dtwp-hepb-ipv-hib) vaccine in comparison with siiplpentavac (dtwp-hepb-hib) + poliovac (ipv) vaccines, administered as separate injections	Dr. Deepak Tayade	Serum Institute of India	Non- Government	Community Medicine	2020	Rs 26,300/- per patient	180 days
24	A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease	Dr. Umar Quadri	GSK	Non- Government	Emergency Medicine	2020	Rs 7,27,291/- per patient	180 days
2020- 2021								
1	Randomized, double-blind, placebo-controlled, parallel-group, multi-centre phaseII/III adaptive clinical trial to assess the safety and immunogenicity, of Gam-COVID-Vac combinedvector vaccine for SARS-CoV-2 infection in Indian Healthy Subjects.	Dr. Anand Nikalje	JSS Medical Research India Pvt Ltd.,	Non Government	General Medicine	2020	16	1 Year
2	Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp Alopecia Areata.	Dr. Ashih Deshmukh	CliniExperts Research Services Private Limited	Non Government	Dermatology	2020	2	1 Year

3	A multicenter, phase II, double blind, randomized, placebo controlled study to evaluate efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of SARS-COV-2/COVID-19 among high risk subjects.	Dr. Tayade Deepak Narayan	Serum Institute of India (SII)	Non Government	Community Medicine	2020	0.5	1 year
3	A Multicenter, Phase III, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subject under.(Amended)	Dr. Tayade Deepak Narayan	DIGNOSEARCH	Non Government	Genral Medicine	2020	26.4	1 Year's
4	Promesa DES - 1: A Prospective, Multicenter, Single arm, Open label Study to Evaluate Safety and Performance of Promesa™ DES Sirolimus Eluting Self-Expandable Nitinol Peripheral Stent System for Treating Superficial Femoral Artery (SFA) and Iliac Artery Lesions.	Dr. Shivaji Pole	Meril Life Science Pvt. Ltd.	Non Government	Radiology	2020	1.5	1 Year's
5	Open label, Randomized, Active-controlled, Multi-centric phase II/III Study in Indian Toddlers and Infants to Assess the Immunogenicity and Safety of SIIPL HEXASIIL™ (DTwP-HepB-IPV-Hib) Vaccine in Comparison to SIIPL Pentavac (DTwP-HepB-Hib) + Poliovac (IPV) vaccines Administered.	Dr. Deepak Tyade	HEXA	Non Government	Pediatric	2020	1.9	1 Year's
6	An open lable, randomized, active controlled, multicentric phase -II/III study in Indian toddlers and infants to assess the immunogenecity and safety of SIIPL HEXASIIL (DTwP-HepB-IPV-Hib) vaccine in comparision with SIIPL Pentavac (DTwP-HepB-Hib) and Poliovac (IPV) vaccines, administered as seperate injections	Dr. Tayade Deepak , Dr. Joshi Bhavna Dr. Engade Madhuri Dr. Joshi Pradnya, Dr. Nela Madhura	Serum Institute of India (SII)	Non Government	Community Medicine & Pediatrics	2020	2.5	3 year
7	A prospective, multi-centre, open lable, phase IV study to evaluate safety and efficacy profile of Infimab™ in patients with moderate to severe plaque psoriasis.	Dr Ashish Deshmukh	Reliance	Non Government	Skin & VD	2020	7.3	1 year

8	A prospective, randomized, two-arm, active-controlled, parallel, Multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% W/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr Ashish Deshmukh	Zydus	Non Government	Skin & VD	2020	2.92	2 year
9	A prospective, Double-Blind, Randomized, Parallel- Group, Vehicle-controlled, Multicentre study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2 % (Supplied By:Glasshouse Pharmaceutical Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Ins; USA) as a Reference product, in subject, with Secondarily Infected Traumatic Skin Lesions.	Dr Ashish Deshmukh	JSS	Non Government	Skin & VD	2020	0.9	1 Year
10	A Phase III, Multicentric, Prospective, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Molnupiravir in Adult Indian Patients with Mild COVID-19.	Dr. Umar Quadri	Hetero Labs Limited	Non Government	General Medicine	2021	3	1 Year
11	A Phase-III, Multicenter, Prospective, Double Blind, Randomized, Parallel Clinical Study Evaluating The Efficacy, Safety And Tolerability Of Hetero-Tocilizumab In Cytokine Storm Of Severe Coronavirus Disease (Covid-19) Pneumonia (TOCICOVID Study).	Dr. Anand Nikalje	Hetero Biopharma Limited	Non Government	General Medicine	2021	23	1 Year
12	A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Noninferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations.	Dr. Mohammed Haseeb	Tergene Biotech Pvt. Ltd	Non Government	Pediatric	2021	7	1 Year

13	A multicentre, prospective, open label, randomized comparative clinical trial to evaluate safety and efficacy of Reliance Life Sciences'Bevacizumab (R-TPR-023) plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) Patients with non-invasive ventilation.	Dr. Anand Nikalje	Reliance life Sciences Pvt. Ltd	Non Government	Genral Medicine	2021	11	1 Year
14	A prospective randopmized double blind multicentric two arms phase 3 clinical trial to assess the efficacy and safety of levobupivacaine in dextrose injection Manufactured by Neon Laboratories LTD. Versus that of Bupivacaine heavy (Bupivacaine hydrochloride in dextrose injection Manufactured by Themis Medicare LTD. for spinal Anesthesia in adult patients.	Dr. V. P. Kelkar(PI) Dr. Dhanjay Bhale	CRO- Biosphere Sponsor- Neon Laboratories	Non Government	Anaesthesia	2021	1.32	On going
15	A multicentre, prospective, open label, randomized comparative clinical trial to evaluate safety and efficacy of Reliance Life Sciences' Bevacizumab (R-TPR-023) plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) Patients with non-invasive ventilation.	Dr. Anand Nikalje	Reliance Life Sciences'	Non Government	Genral Medicine	2021	11.15	1 Year's
16	AZ-C-MVL-18-101-A Prospective Randomized Double Blind Multicentric Two Arms Phase III Clinical Trial To Assess the Efficacy And safety of levobupivacaine in Dextrose injection manufactured by Neon Laboratories Ltd. Cersus that of Bupicain Heavy (Bupivacaine Hydrochloride In Dextrose Injection) Manufactured By Thmis Medicare Ltd. for Spinal Anaesthsia inb Adult Patients.	Dr. Kelkar Vasanti Prabhakar	Biosphere Clinical Research Pvt. Ltd	Non Government	Anesthesia	2021	0.5	1 Year

2021-2022

1	Randomized double blinded placebo controlled parralal group multicenter phase II/III adaptive clinical trial to assess the safety and immunogenicity of gam-COVID-vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Non-Government	Medicine	2021	496059	02 Year
2	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr. Ashish Deshmukh	Zydus (Grapecity)	Non-Government	Dermatology	2021	140918 59015	01 Year
3	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr. Umar Quedri	PPD(Doclin C.)	Non-Government	Medicine	2021	20000 1367500	02 Year
4	A streamlined, multicenter, randomized, parallel group, double blind placebo controlled, superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with acute myocardial infarction.	Dr. Prashant Udgire	Covance	Non-Government	Pharmacology	2021	55500	01 year
5	A Prospective, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2%(Supplied by: Glasshouse Pharmaceuticals Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Inc; USA) as a Reference Product, in Subjects with Secondarily Infected Traumatic Skin Lesions	Dr. Ashish Deshmukh	JSS (Grapecity)	Non Government	Dermatology	2021	84647	2 year

6	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19.	Dr. Anand Nikaje	IQVIA (Grapecity)	Non Government	Medicine	2021	153356	01 year
7	A Prospective, Multi-centre, Phase IV Study to Assess the Safety, Efficacy and Immunogenicity of BIOSULIN® 30:70 (Insulin Injection, Biphasic Isophane 100 IU/ml of M.J. Biopharm Private Limited) in Treatment of Patients Diagnosed with Type 2 Diabetes Mellitus	Dr. Umar Quadri	Abionene	Non-Government	Medicine	2021	27625	01 Year
8	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr. Umar Quadri	PPD Pharma (Docclin C.)	Non-Government	Medicine	2021	328557	02 year
9	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm (Ardent Clinical Research)	Non Government	Radiology	2021	94041	01 Year
10	A Prospective, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2% (Supplied by: Glasshouse Pharmaceuticals Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Inc; USA) as a Reference Product, in Subjects with Secondarily Infected Traumatic Skin Lesions	Dr. Ashish Deshmukh	JSS (Grapecity)	Non Government	Dermatology	2021	7389	2 Year
11	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as	Dr. Ashish Deshmukh	Zydus (Grapecity)	Non Government	Dermatology	2021	10080	2 Year

12	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Dignosearch)	Non Government	Community Medicine	2021	581005.5	01 year
							13500	
							3500	
13	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr. Ashish Deshmukh	Zydus (Grapecity)	Non Government	Dermatology	2021	128250	02 year
14	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Non Government	Medicine	2021	630180	02 year
15	A Phase III, Multicentre, Randomized, Double Blind, Parallel group, Comparative Clinical Study to evaluate Efficacy and Safety of RopivacaineHydrochloride 0.75% (7.5mg/mL) in Dextrose 8% (80mg/mL) injection compared to Bupivacaine Hydrochloride 0.5% (5mg/mL) in Dextrose 8% (80mg/mL) injection for subjects undergoing lower limb orthopaedic surgeries under spinal anaesthesia.	Dr. Vasanti Kalkar	Bioshpere	Non Government	Anaesthesia	2021	28800	2 year
16	A prospective, multi-centre, open label, phase IV studyto evaluate safety and efficacy profile of Infimab™ inpatients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance (Grapecity)	Non Government	Dermatology	2021	140036	01 year

17	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokinerelease syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19	Dr. Anand Nikaje	Biocon (Grapecity)	Non Government	Department of Medicine	2021	146795	01 year
18	Randomized double blinded placebo controlled parralal group multicenter phase II/III adaptive clinical trial to assess the safety and immunogenicity of gam-COVID-vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Non Government	Department of Medicine	2021	94770	01 year
19	A multicentre, phase iii, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of Sars-Cov-2/ Covid-19 Among High-Risk Subjects	Dr. Deepak Tayade	Serum	Non Government	Community Medicine	2021	500	01 year
20	A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled study to evaluate the efficacy and safety of Ketorolac 30 mg sublingual tablet in the acute treatment of migraine headache.	Dr.Manjiri Naik	Syneos	Non Government	Medicine	2021	83333	01 year
21	RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19	Dr, Anand Nikalje	Clinixel	Non Government	Medicine	2021	83250	01 year
22	A prospective, randomized, parallel, multicentric, phase III clinical trial to assess the efficacy and safety of Molnupiravir 800 mgcapsules and standard of care (soc) compared to standard of care (soc) only in patients with polymerase chain reaction (RT-PCR)confirmed Mild Covid-19 infection.	Dr, Anand Nikalje	Clinenfinity	Non Government	Medicine	2021	104643	01 year
23	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery	Dr. Girish Gadekar	PPD Pharma	Non Government	Orthopedics	2021	75006	01 year

24	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab™ inpatients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance (Grapecity)	Non Government	Dermatology	2021	376866	2 year
25	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Diagnosearch)	Non Government	Community Medicine	2021	50000	2 year
26	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Diagnosearch)	Non Government	Community Medicine		1118230	01 year
27	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19.	Dr. Anand Nikaje	Biocon (Grapecity)	Non Government	Medicine	2021	30303	2 Year
28	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab™ inpatients with moderate to severe plaque psoriasis.	Dr. Ashish Deshmukh	Reliance (Grapecity)	Non Government	Dermatology	2021	77501	2 Year
29	A Phase-III, Multicenter, Prospective, Double Blind, Randomized, Parallel Clinical Study Evaluating The Efficacy, Safety And Tolerability Of Hetero-Tocilizumab In Cytokine Storm Of Severe Coronavirus Disease (Covid-19) Pneumonia (TOCICOVID Study)	Dr. Anand Nikaje	HETRO (Grapecity)	Non Government	Medicine	2021	1163565	2 Year
30	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm (Reliance)	Non Government	Radiology	2021	121500	2 Year

31	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (PPD Pharma)	Non Government	Medicine	2021	25002	2 Year
32	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm (Ardent clinical Research)	Non Government	Radiology	2021	78106	2 Year
33	A phase two study to evaluate the testicular safety of a nw oral drugs in adult male patient with active alcerative collitties.	Dr.Ashok Mohite	Vedic Life sciences	Non Government	Surgery	2021	74250	1 year
34	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Non Government	Medicine	2021	82485	2 Year
35	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS	Non Government	Medicine	2021	26730	3 Year
36	A multicentre, phase III, double-blind, randomized, placebocontrolled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of Sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum	Non Government	Community Medicine	2021	12000	1 year
37	A Randomized. Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema	Dr. Deepak Bhosle Dr. Swapnil Dongaokar	Syneos	Non Government	Pharmacology	2021	27778	1 year
38	A Randomized, Double-blind, Parallel Arm, Multicenter Study to Evaluate the Efficacy and Safety of Nitric Oxide Nasal Spray Combined with Standard Supportive Care in Adult non-hospitalized Patients With COVID- 19.	Dr. Anand Nikaje	Gelmark (Grapecity)	Non Government	Medicine	2021	550602	1 year
							55890	1 year

39	A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension.	Dr. Deepak Bhosle	IQVIA	Non Government	Pharmacology	2021	100000.8	1 year
40	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery	Dr. Girish Gadekar	PPD Pharma	Non Government	Orthopedics	2021	50001	1 year